199 related articles for article (PubMed ID: 35306319)
1. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.
Wu YH; Hung YP; Chiu NC; Lee RC; Li CP; Chao Y; Shyr YM; Wang SE; Chen SC; Lin SH; Chen YH; Kang YM; Hsu SM; Yen SH; Wu JY; Lee KD; Tseng HE; Tsai JR; Tang JH; Chiou JF; Burnouf T; Chen YJ; Wang PY; Lu LS
Eur J Cancer; 2022 May; 166():208-218. PubMed ID: 35306319
[TBL] [Abstract][Full Text] [Related]
2. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
3. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
[TBL] [Abstract][Full Text] [Related]
4. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer.
Chen J; Wang H; Zhou L; Liu Z; Tan X
J Clin Lab Anal; 2022 May; 36(5):e24341. PubMed ID: 35334495
[TBL] [Abstract][Full Text] [Related]
5. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.
Varillas JI; Zhang J; Chen K; Barnes II; Liu C; George TJ; Fan ZH
Theranostics; 2019; 9(5):1417-1425. PubMed ID: 30867841
[No Abstract] [Full Text] [Related]
6. Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma.
Liu H; Sun B; Wang S; Liu C; Lu Y; Li D; Liu X
Cell Physiol Biochem; 2017; 42(1):373-382. PubMed ID: 28558380
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
[TBL] [Abstract][Full Text] [Related]
8. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.
Stoecklein NH; Fluegen G; Guglielmi R; Neves RPL; Hackert T; Birgin E; Cieslik SA; Sudarsanam M; Driemel C; van Dalum G; Franken A; Niederacher D; Neubauer H; Fehm T; Rox JM; Böhme P; Häberle L; Göring W; Esposito I; Topp SA; Coumans FAW; Weitz J; Knoefel WT; Fischer JC; Bork U; Rahbari NN
Mol Cancer; 2023 Nov; 22(1):181. PubMed ID: 37957606
[TBL] [Abstract][Full Text] [Related]
9. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
10. PDX-derived organoids model in vivo drug response and secrete biomarkers.
Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
14. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
[TBL] [Abstract][Full Text] [Related]
15. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer.
Semaan A; Bernard V; Kim DU; Lee JJ; Huang J; Kamyabi N; Stephens BM; Qiao W; Varadhachary GR; Katz MH; Shen Y; San Lucas FA; Gascoyne P; Alvarez HA; Maitra A; Guerrero PA
Br J Cancer; 2021 Jun; 124(12):1970-1977. PubMed ID: 33785875
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.
Yeo D; Bastian A; Strauss H; Saxena P; Grimison P; Rasko JEJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163592
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
